Ragan SP - Search Results

1

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.

Qin JS, Johnstone TG, Baturevych A, Hause RJ, Ragan SP, Clouser CR, Jones JC, Ponce R, Krejsa CM, Salmon RA, Ports MO. Qin JS, et al. Among authors: ragan sp. J Immunother. 2020 May;43(4):107-120. doi: 10.1097/CJI.0000000000000307. J Immunother. 2020. PMID: 31899702 Free PMC article.

2

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.

Olson NE, Ragan SP, Reiss DJ, Thorpe J, Kim Y, Abramson JS, McCoy C, Newhall KJ, Fox BA. Olson NE, et al. Among authors: ragan sp. Mol Cancer Ther. 2023 Mar 2;22(3):406-418. doi: 10.1158/1535-7163.MCT-21-0506. Mol Cancer Ther. 2023. PMID: 36595660 Free PMC article.

3

Expamers: a new technology to control T cell activation.

Poltorak MP, Graef P, Tschulik C, Wagner M, Cletiu V, Dreher S, Borjan B, Fraessle SP, Effenberger M, Turk M, Busch DH, Plitzko J, Kugler DG, Ragan S, Schmidt T, Stemberger C, Germeroth L. Poltorak MP, et al. Among authors: ragan s. Sci Rep. 2020 Oct 20;10(1):17832. doi: 10.1038/s41598-020-74595-8. Sci Rep. 2020. PMID: 33082362 Free PMC article.

4

Measurement of Cancer Cell Growth Heterogeneity through Lentiviral Barcoding Identifies Clonal Dominance as a Characteristic of In Vivo Tumor Engraftment.

Nolan-Stevaux O, Tedesco D, Ragan S, Makhanov M, Chenchik A, Ruefli-Brasse A, Quon K, Kassner PD. Nolan-Stevaux O, et al. PLoS One. 2013 Jun 26;8(6):e67316. doi: 10.1371/journal.pone.0067316. Print 2013. PLoS One. 2013. PMID: 23840661 Free PMC article.

5

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.

Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, Milburn RR, Siu S, Ragan SP, Rock DA, Borths CJ, O'Neill JW, Chang WS, Weidner MF, Bio MM, Quon KC, Fanslow WC. Hamblett KJ, et al. Among authors: ragan sp. Cancer Res. 2015 Dec 15;75(24):5329-40. doi: 10.1158/0008-5472.CAN-15-1610. Epub 2015 Dec 2. Cancer Res. 2015. PMID: 26631267

6

Structure--activity relationships of lysophosphatidic acid: conformationally restricted backbone mimetics.

Hopper DW, Ragan SP, Hooks SB, Lynch KR, Macdonald TL. Hopper DW, et al. Among authors: ragan sp. J Med Chem. 1999 Mar 25;42(6):963-70. doi: 10.1021/jm970809v. J Med Chem. 1999. PMID: 10090779

7

Identification of a novel human phosphatidic acid phosphatase type 2 isoform.

Hooks SB, Ragan SP, Lynch KR. Hooks SB, et al. Among authors: ragan sp. FEBS Lett. 1998 May 8;427(2):188-92. doi: 10.1016/s0014-5793(98)00421-9. FEBS Lett. 1998. PMID: 9607309 Free article.

8

Characterization of a receptor subtype-selective lysophosphatidic acid mimetic.

Hooks SB, Ragan SP, Hopper DW, Hönemann CW, Durieux ME, Macdonald TL, Lynch KR. Hooks SB, et al. Among authors: ragan sp. Mol Pharmacol. 1998 Feb;53(2):188-94. doi: 10.1124/mol.53.2.188. Mol Pharmacol. 1998. PMID: 9463475

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters